Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alector Inc.
Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.
Alector says upfront payment and earnouts will fully pay for development of AL101 and AL001 in frontotemporal dementia and indications including ALS, Alzheimer’s and Parkinson’s.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.
Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Alector LLC